查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
北美微生物组治疗市场预测至 2030 年 - 区域分析 - 按类型、应用和最终用户
市场调查报告书
商品编码
1494520

北美微生物组治疗市场预测至 2030 年 - 区域分析 - 按类型、应用和最终用户

North America Microbiome Therapeutics Market Forecast to 2030 - Regional Analysis - by Type, Application, and End User
出版日期: | 出版商: The Insight Partners | 英文 68 Pages | 订单完成后即时交付

价格

2022年北美微生物组治疗市值为1.6164亿美元，预计2030年将达到3.4299亿美元；预计2022年至2030年复合年增长率为9.9%。

改善微生物组发现管道的资金流入推动北美微生物组治疗市场

研究表明，微生物群的不平衡或破坏可能导致多种疾病，例如发炎性肠道疾病和肥胖，以及精神健康障碍。微生物组在整体健康中的作用的认识引起了人们对开发针对和调节微生物组的疗法的浓厚兴趣。此外，技术和研究工具的进步使得研究和操纵微生物组变得更加容易。新一代定序和宏基因组分析使人们能够更深入地了解微生物群落及其功能。知识的增加为开发标靶疗法开启了新的可能性。美国食品药物管理局（FDA）等监管机构也表示愿意支持微生物疗法的开发。 FDA 制定了 FMT 指南，并表示有兴趣透过确保安全性和有效性的监管途径来推进该领域的发展。所有这些因素结合起来，为微生物组治疗领域的公司创造了有利的投资环境。

随着强有力的临床证据的出现，投资人开始注意到微生物组调节剂公司。增加的资金为公司提供了必要的资源，以克服与开发和生产高成本相关的挑战，最终推动该领域向前发展。

北美微生物组治疗市场概述

人们越来越了解人类微生物组在维持健康和预防疾病方面的重要性，促使美国研究人员探索基于微生物组的干预措施，将其作为治疗各种疾病的有前景的方法。此外，该国在北美微生物组治疗市场的主导地位主要归功于其发达的研究基础设施，有利于创新疗法的开发此外，肥胖和炎症性肠道疾病等慢性病患病率的上升创造了需求创新治疗，刺激微生物组疗法的发展。基因定序和生物资讯学的技术进步使得微生物组的研究和改变成为可能，从而促进基于微生物组的个人化干预措施的发展。个人化医疗的趋势与客製化微生物组疗法非常吻合。学术界、工业界和政府组织之间的合作也正在推动研究和开发工作，加速将科学发现转化为商业产品。由于监管机构认识到微生物组疗法的潜力并为其开发和批准提供指导，该领域的监管支持和投资进一步促进了市场成长。

北美微生物组治疗市场收入及 2030 年预测（百万美元）

北美微生物组治疗市场细分

北美微生物组治疗市场根据类型、应用、最终用户和国家进行细分。

根据类型，北美微生物组治疗市场分为治疗方法和手术方法。到 2022 年，手术细分市场将占据更大份额。

根据应用，北美微生物组治疗市场分为代谢紊乱和肥胖、艰难梭菌感染、发炎性肠道疾病等。 2022 年，艰难梭菌感染部分占最大份额。

从最终用户来看，北美微生物组治疗市场包括医院和诊所、门诊手术中心、家庭护理等。 2022 年，医院和诊所领域占最大份额。

根据国家/地区，北美微生物组治疗市场分为美国、加拿大和墨西哥。 2022 年，美国将主导北美微生物组治疗市场。

AOBiome Therapeutics Inc、Ferring Holdings SA、Finch Therapeutics Group Inc、Pendulum Therapeutics Inc 和 Seres Therapeutics Inc 是北美微生物组治疗市场上的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：北美微生物组治疗市场格局

  • 概述
  • 北美 PEST 分析

第 5 章：北美微生物组治疗市场 - 主要产业动态

  • 北美微生物组治疗市场 - 主要产业动态
  • 主要市场驱动因素
    • 肠道微生物群在维持人类健康的潜力
    • 资金流入改善微生物组发现管道
  • 主要市场限制
    • 开发和生产成本高
  • 主要市场机会
    • 加强研发以更了解人类微生物组
  • 未来主要趋势
    • 人类微生物组治疗的技术进步
  • 驱动因素和限制的影响：

第 6 章：微生物组治疗市场 - 北美市场分析

第 7 章：北美微生物组治疗市场分析 - 类型

  • 疗法
    • 概述
    • 治疗市场、收入与 2030 年预测
  • 程式
    • 概述
    • 程序市场、收入与 2030 年预测

第 8 章：北美微生物组治疗市场分析 - 应用

  • 代谢紊乱与肥胖
    • 概述
    • 代谢紊乱和肥胖市场、收入和 2030 年预测
  • C. 艰难梭菌感染 (CDI)
    • 概述
    • C. 艰难梭菌感染 (CDI) 市场、收入和 2030 年预测
  • 发炎性肠道疾病
    • 概述
    • 发炎性肠道疾病市场、收入和 2030 年预测
  • 其他的
    • 概述
    • 其他市场、收入和 2030 年预测

第 9 章：北美微生物组治疗市场分析 - 最终用户

  • 医院和诊所
    • 概述
    • 医院和诊所市场、收入和 2030 年预测
  • 门诊手术中心
    • 概述
    • 门诊手术中心市场、收入与 2030 年预测
  • 居家护理
    • 概述
    • 家庭护理市场、收入和 2030 年预测
  • 其他的
    • 概述
    • 其他市场、收入和 2030 年预测

第 10 章：北美微生物组治疗市场 - 国家分析

  • 我们
  • 加拿大
  • 墨西哥

第 11 章：产业格局

  • 概述
  • 北美微生物组治疗市场的成长策略

第 12 章：公司简介

  • Ferring Holdings SA
  • Vedanta Biosciences Inc
  • Finch Therapeutics Group Inc
  • Pendulum Therapeutics Inc
  • Seres Therapeutics Inc
  • AOBiome Therapeutics Inc

第 13 章：附录

Product Code: BMIRE00029954

The North America microbiome therapeutics market was valued at US$ 161.64 million in 2022 and is expected to reach US$ 342.99 million by 2030; it is estimated to record a CAGR of 9.9% from 2022 to 2030.

Inflow of Funds to Ameliorate Microbiome Discovery Pipeline Drives North America Microbiome Therapeutics Market

Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome's role in overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. Regulatory agencies such as the US Food and Drug Administration (FDA) have also shown a willingness to support the development of microbiome therapeutics. The FDA has established guidelines for FMT and has expressed interest in advancing the field through regulatory pathways that ensure safety and efficacy. All these factors combined have created a favorable investment climate for companies working in the field of microbiome therapeutics.

As strong clinical evidence becomes available, investors are beginning to take notice of microbiome modulator firms. The heightened funding provides companies with necessary resources to overcome the challenges associated with the high cost of development and production, ultimately driving the field forward.

North America Microbiome Therapeutics Market Overview

The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treating various conditions. Additionally, the dominance of this country in the North America microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments Further, the rising prevalence of chronic diseases such as obesity and inflammatory bowel disease has created a demand for innovative treatments, spurring the development of microbiome therapeutics. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics. Collaborations between academia, industry, and government organizations are also fueling research and development efforts, accelerating the translation of scientific discoveries into commercial products. Regulatory support and investment in the field further contribute to market growth, as regulatory bodies recognize the potential of microbiome therapeutics and provide guidance for their development and approval.

North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

North America Microbiome Therapeutics Market Segmentation

The North America microbiome therapeutics market is segmented based on type, application, end user, and country.

Based on type, the North America microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held a larger share in 2022. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.

By application, the North America microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The C. difficile infection segment held the largest share in 2022.

By end user, the North America microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held the largest share in 2022.

Based on country, the North America microbiome therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America microbiome therapeutics market in 2022.

AOBiome Therapeutics Inc, Ferring Holdings SA, Finch Therapeutics Group Inc, Pendulum Therapeutics Inc, and Seres Therapeutics Inc are some of the leading companies operating in the North America microbiome therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Microbiome Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 North America PEST Analysis

5. North America Microbiome Therapeutics Market - Key Industry Dynamics

  • 5.1 North America Microbiome Therapeutics Market - Key Industry Dynamics
  • 5.2 Key Market Drivers
    • 5.2.1 Potential of Gut Microbiota in Maintaining Human Health
    • 5.2.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
  • 5.3 Key Market Restraints
    • 5.3.1 High Cost of Development and Production
  • 5.4 Key Market Opportunities
    • 5.4.1 Increasing R&D to Gain Better Understanding of Human Microbiome
  • 5.5 Key Future Trends
    • 5.5.1 Technological Advancement in Human Microbiome Therapeutics
  • 5.6 Impact of Drivers and Restraints:

6. Microbiome Therapeutics Market - North America Market Analysis

7. North America Microbiome Therapeutics Market Analysis - Type

  • 7.1 Therapeutics
    • 7.1.1 Overview
    • 7.1.2 Therapeutics Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 7.2 Procedure
    • 7.2.1 Overview
    • 7.2.2 Procedure Market, Revenue and Forecast to 2030 (US$ Thousand)

8. North America Microbiome Therapeutics Market Analysis - Application

  • 8.1 Metabolic Disorder and Obesity
    • 8.1.1 Overview
    • 8.1.2 Metabolic Disorder and Obesity Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.2 C. Difficile Infection (CDI)
    • 8.2.1 Overview
    • 8.2.2 C. Difficile Infection (CDI) Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.3 Inflammatory Bowel Disease
    • 8.3.1 Overview
    • 8.3.2 Inflammatory Bowel Disease Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

9. North America Microbiome Therapeutics Market Analysis - End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Overview
    • 9.1.2 Hospitals and Clinics Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.2 Ambulatory Surgical Centers
    • 9.2.1 Overview
    • 9.2.2 Ambulatory Surgical Centers Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.3 Homecare
    • 9.3.1 Overview
    • 9.3.2 Homecare Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

10. North America Microbiome Therapeutics Market - Country Analysis

  • 10.1 North America Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
    • 10.1.1 North America Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
    • 10.1.2 US
      • 10.1.2.1 US: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.2.2 US: North America Microbiome Therapeutics Market Breakdown by Type
        • 10.1.2.2.1 US North America Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.2.3 US: North America Microbiome Therapeutics Market Breakdown by Application
      • 10.1.2.4 US: North America Microbiome Therapeutics Market Breakdown by End User
    • 10.1.3 Canada
      • 10.1.3.1 Canada: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.3.2 Canada: North America Microbiome Therapeutics Market Breakdown by Type
        • 10.1.3.2.1 Canada North America Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.3.3 Canada: North America Microbiome Therapeutics Market Breakdown by Application
      • 10.1.3.4 Canada: North America Microbiome Therapeutics Market Breakdown by End User
    • 10.1.4 Mexico
      • 10.1.4.1 Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.4.2 Mexico: North America Microbiome Therapeutics Market Breakdown by Type
        • 10.1.4.2.1 Mexico: North America Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.4.3 Mexico: North America Microbiome Therapeutics Market Breakdown by Application
      • 10.1.4.4 Mexico: North America Microbiome Therapeutics Market Breakdown by End User

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in North America Microbiome Therapeutics Market

12. Company Profiles

  • 12.1 Ferring Holdings SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Vedanta Biosciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Finch Therapeutics Group Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Pendulum Therapeutics Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Seres Therapeutics Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 AOBiome Therapeutics Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. North America Microbiome Therapeutics Market Segmentation
  • Table 2. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - Type
  • Table 3. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - Therapeutics
  • Table 4. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - Application
  • Table 5. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - End User
  • Table 6. North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Country
  • Table 7. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 8. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 9. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 10. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 11. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 12. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 13. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 14. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 15. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 16. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 17. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 18. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 19. Recent Growth Strategies in North America Microbiome Therapeutics Market
  • Table 20. Glossary of Terms, North America Microbiome Therapeutics Market

List Of Figures

  • Figure 1. North America Microbiome Therapeutics Market Segmentation, By Country
  • Figure 2. North America PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Microbiome Therapeutics Market Revenue (US$ Thousand), 2022 - 2030
  • Figure 5. North America Microbiome Therapeutics Market Share (%) - Type, 2022 and 2030
  • Figure 6. Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 7. Procedure Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 8. North America Microbiome Therapeutics Market Share (%) - Application, 2022 and 2030
  • Figure 9. Metabolic Disorder and Obesity Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 10. C. Difficile Infection (CDI) Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 11. Inflammatory Bowel Disease Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 12. Others Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 13. North America Microbiome Therapeutics Market Share (%) - End User, 2022 and 2030
  • Figure 14. Hospitals and Clinics Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 15. Ambulatory Surgical Centers Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 16. Homecare Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 17. Others Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 18. North America Microbiome Therapeutics Market Breakdown by Key Countries - Revenue (2022) (US$ Thousand)
  • Figure 19. North America Microbiome Therapeutics Market Breakdown by Key Countries, 2022 and 2030 (%)
  • Figure 20. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 21. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 22. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)